REGENXBIO Completes Enrollment in Pivotal Sura-Vec Trials and Reports Q3 2026 Financials
REGENXBIO has finished enrolling over 1,300 patients in its pivotal ATMOSPHERE and ASCENT clinical trials for sura-vec, with data expected in Q4 2026.
Stocks · News reference
Mizuho maintained an Outperform rating on REGENXBIO while lowering its price target from $19 to $18.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
REGENXBIO has finished enrolling over 1,300 patients in its pivotal ATMOSPHERE and ASCENT clinical trials for sura-vec, with data expected in Q4 2026.
Regenxbio (NASDAQ:RGNX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
REGENXBIO Inc. reported its third-quarter 2026 financial results, highlighting a narrowed net loss driven by a litigation settlement gain and providing an update on its clinical pipeline.
Filed: 2026-11-05 AccNo: 0001193125-26-448559 Size: 529 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
REGENXBIO Inc. announced it will participate in the upcoming Stifel 2026 Healthcare Conference, featuring a fireside chat.
Mizuho Securities analyst Graig Suvannavejh maintained a 'Buy' rating on REGENXBIO shares while lowering the price target from $22 to $19.